{"id": "article-143125_0", "title": "Parkinson-Plus Syndrome -- Continuing Education Activity", "content": "Parkinson-plus syndromes are characterized by the primary features of Parkinson disease, including bradykinesia, ataxia, resting tremor, and rigidity but also include additional features such as dementia, cognitive deficits, and cranial nerve impairment. These chronic, debilitating neurodegenerative conditions result in severe impairment and are typically idiopathic. Differential diagnosis can lead to improved symptom management, but definitive diagnosis requires the identification of alpha-synuclein or tau inclusions in the brain post-mortem. This activity reviews the evaluation and treatment of Parkinson-plus syndromes and highlights the role of the interprofessional team in managing patients with these conditions.", "contents": "Parkinson-Plus Syndrome -- Continuing Education Activity. Parkinson-plus syndromes are characterized by the primary features of Parkinson disease, including bradykinesia, ataxia, resting tremor, and rigidity but also include additional features such as dementia, cognitive deficits, and cranial nerve impairment. These chronic, debilitating neurodegenerative conditions result in severe impairment and are typically idiopathic. Differential diagnosis can lead to improved symptom management, but definitive diagnosis requires the identification of alpha-synuclein or tau inclusions in the brain post-mortem. This activity reviews the evaluation and treatment of Parkinson-plus syndromes and highlights the role of the interprofessional team in managing patients with these conditions."}
{"id": "article-143125_1", "title": "Parkinson-Plus Syndrome -- Continuing Education Activity", "content": "Objectives: Describe the pathophysiology of the various Parkinson-plus syndromes. Outline the unique clinical presentation of each Parkinson-plus condition. Review the differential diagnostic methods incorporated in the medical workup of Parkinson-plus syndromes. Summarize the treatment options available and their potential effects. Access free multiple choice questions on this topic.", "contents": "Parkinson-Plus Syndrome -- Continuing Education Activity. Objectives: Describe the pathophysiology of the various Parkinson-plus syndromes. Outline the unique clinical presentation of each Parkinson-plus condition. Review the differential diagnostic methods incorporated in the medical workup of Parkinson-plus syndromes. Summarize the treatment options available and their potential effects. Access free multiple choice questions on this topic."}
{"id": "article-143125_2", "title": "Parkinson-Plus Syndrome -- Introduction", "content": "Parkinson-plus syndrome (PPS), also called atypical parkinsonism, refers to a group of neurodegenerative movement disorders that resemble idiopathic Parkinson's disease (PD) with certain distinguishing clinical and pathophysiological features. [1] As in classical Parkinson disease, the primary symptoms of parkinsonism present include\u00a0apraxia, rigidity, bradykinesia, tremor, and postural instability. Distinctive features of PPS include early-onset dementia, hallucinations, dysautonomia, gaze palsy, myoclonus, pyramidal tract signs, and alien limb phenomenon. [2]", "contents": "Parkinson-Plus Syndrome -- Introduction. Parkinson-plus syndrome (PPS), also called atypical parkinsonism, refers to a group of neurodegenerative movement disorders that resemble idiopathic Parkinson's disease (PD) with certain distinguishing clinical and pathophysiological features. [1] As in classical Parkinson disease, the primary symptoms of parkinsonism present include\u00a0apraxia, rigidity, bradykinesia, tremor, and postural instability. Distinctive features of PPS include early-onset dementia, hallucinations, dysautonomia, gaze palsy, myoclonus, pyramidal tract signs, and alien limb phenomenon. [2]"}
{"id": "article-143125_3", "title": "Parkinson-Plus Syndrome -- Introduction", "content": "Unlike Parkinson disease, these conditions have a limited response to levodopa with a poor overall prognosis. [3] The most common PPS conditions are Lewy body dementia (LBD), multiple system atrophy (MSA), corticobasal degeneration (CBD), and progressive supranuclear palsy (PSP). [2] [4]", "contents": "Parkinson-Plus Syndrome -- Introduction. Unlike Parkinson disease, these conditions have a limited response to levodopa with a poor overall prognosis. [3] The most common PPS conditions are Lewy body dementia (LBD), multiple system atrophy (MSA), corticobasal degeneration (CBD), and progressive supranuclear palsy (PSP). [2] [4]"}
{"id": "article-143125_4", "title": "Parkinson-Plus Syndrome -- Introduction", "content": "Less prevalent disorders are frontotemporal dementia, Pick disease, pallidonigral degeneration, parkinsonian-dementia complex of Guam, Wilson disease, and a rigid variant of Huntington disease. [5] [6] This review will discuss the most common PPS conditions, focusing on epidemiology, etiology, pathophysiology, evaluation, and treatment options.", "contents": "Parkinson-Plus Syndrome -- Introduction. Less prevalent disorders are frontotemporal dementia, Pick disease, pallidonigral degeneration, parkinsonian-dementia complex of Guam, Wilson disease, and a rigid variant of Huntington disease. [5] [6] This review will discuss the most common PPS conditions, focusing on epidemiology, etiology, pathophysiology, evaluation, and treatment options."}
{"id": "article-143125_5", "title": "Parkinson-Plus Syndrome -- Etiology", "content": "The vast majority of Parkinson-plus syndrome cases occur sporadically, and the precise etiology remains unknown.\u00a0A few examples of familial cases suggest that genetics may play a role in the pathogenesis of PPS. [7] Environmental factors additionally contribute to the evolution of these diseases. [8]", "contents": "Parkinson-Plus Syndrome -- Etiology. The vast majority of Parkinson-plus syndrome cases occur sporadically, and the precise etiology remains unknown.\u00a0A few examples of familial cases suggest that genetics may play a role in the pathogenesis of PPS. [7] Environmental factors additionally contribute to the evolution of these diseases. [8]"}
{"id": "article-143125_6", "title": "Parkinson-Plus Syndrome -- Epidemiology -- Lewy Body Dementia", "content": "LBD is one of the most common causes of neurodegenerative dementia, accounting for up to 30 percent of all dementia cases.\u00a0The only forms of dementia more common are Alzheimer disease (AD) and vascular dementia.\u00a0The prevalence is estimated to be 5 percent of the general population, and the incidence is approximately 0.1 percent annually. [9] [10]", "contents": "Parkinson-Plus Syndrome -- Epidemiology -- Lewy Body Dementia. LBD is one of the most common causes of neurodegenerative dementia, accounting for up to 30 percent of all dementia cases.\u00a0The only forms of dementia more common are Alzheimer disease (AD) and vascular dementia.\u00a0The prevalence is estimated to be 5 percent of the general population, and the incidence is approximately 0.1 percent annually. [9] [10]"}
{"id": "article-143125_7", "title": "Parkinson-Plus Syndrome -- Epidemiology -- Multiple System Atrophy", "content": "The approximate prevalence of MSA ranges from 2 to 5 cases per 100,000, and the\u00a0incidence is 3 per 100,000.\u00a0The mean age of onset is estimated to be 54 years. Men and women are affected equally. [11]", "contents": "Parkinson-Plus Syndrome -- Epidemiology -- Multiple System Atrophy. The approximate prevalence of MSA ranges from 2 to 5 cases per 100,000, and the\u00a0incidence is 3 per 100,000.\u00a0The mean age of onset is estimated to be 54 years. Men and women are affected equally. [11]"}
{"id": "article-143125_8", "title": "Parkinson-Plus Syndrome -- Epidemiology -- Corticobasal Degeneration", "content": "The approximate annual incidence of CBD ranges between 0.62 to 0.92 per 100,000, and the prevalence ranges from 5 to 7 per 100,000. [12] The disease typically presents at a mean age of 61 to 64 years. There is a suggested predominance of females.", "contents": "Parkinson-Plus Syndrome -- Epidemiology -- Corticobasal Degeneration. The approximate annual incidence of CBD ranges between 0.62 to 0.92 per 100,000, and the prevalence ranges from 5 to 7 per 100,000. [12] The disease typically presents at a mean age of 61 to 64 years. There is a suggested predominance of females."}
{"id": "article-143125_9", "title": "Parkinson-Plus Syndrome -- Epidemiology -- Progressive Supranuclear Palsy", "content": "The approximate prevalence of PSP is 3 to 7 per 100,000.\u00a0The approximate incidence is 1.1 per 100,000 person-years. [12]", "contents": "Parkinson-Plus Syndrome -- Epidemiology -- Progressive Supranuclear Palsy. The approximate prevalence of PSP is 3 to 7 per 100,000.\u00a0The approximate incidence is 1.1 per 100,000 person-years. [12]"}
{"id": "article-143125_10", "title": "Parkinson-Plus Syndrome -- Pathophysiology", "content": "The pathophysiology of PPS can be divided into two groups, alpha-synucleinopathies and tauopathies. These groups allude to the type of protein (alpha-synuclein and tau proteins) which folds into a toxic and cell-damaging form. [1] [2] It is proposed that the misfolded, toxic proteins cause cell death and induce improper folding of other proteins as the disease spreads throughout the brain. [2]", "contents": "Parkinson-Plus Syndrome -- Pathophysiology. The pathophysiology of PPS can be divided into two groups, alpha-synucleinopathies and tauopathies. These groups allude to the type of protein (alpha-synuclein and tau proteins) which folds into a toxic and cell-damaging form. [1] [2] It is proposed that the misfolded, toxic proteins cause cell death and induce improper folding of other proteins as the disease spreads throughout the brain. [2]"}
{"id": "article-143125_11", "title": "Parkinson-Plus Syndrome -- Pathophysiology", "content": "In tauopathies such as PSP and CBD, cytoskeleton proteins become abnormally phosphorylated, leading to the development of tau inclusions in neurons and glial cells. [4] A similar process occurs in the alpha-synucleinopathies PD, LBD, and MSA. [6] The specific inclusions formed by alpha-synuclein are referred to as Lewy bodies in PD and LBD. [6] It is unknown why tau and alpha-synuclein proteins originally misfold, but it is postulated that it is due to sporadic mutations and environmental factors. [1] [2] The specific\u00a0PPS condition is related to the type of neurons targeted and the location of these toxic proteins in the brain.", "contents": "Parkinson-Plus Syndrome -- Pathophysiology. In tauopathies such as PSP and CBD, cytoskeleton proteins become abnormally phosphorylated, leading to the development of tau inclusions in neurons and glial cells. [4] A similar process occurs in the alpha-synucleinopathies PD, LBD, and MSA. [6] The specific inclusions formed by alpha-synuclein are referred to as Lewy bodies in PD and LBD. [6] It is unknown why tau and alpha-synuclein proteins originally misfold, but it is postulated that it is due to sporadic mutations and environmental factors. [1] [2] The specific\u00a0PPS condition is related to the type of neurons targeted and the location of these toxic proteins in the brain."}
{"id": "article-143125_12", "title": "Parkinson-Plus Syndrome -- Pathophysiology -- Lewy Body Dementia (LBD)", "content": "In LBD, alpha-synuclein dysfunction and associated Lewy body deposits contribute to the impairment of particularly susceptible dopaminergic and cholinergic neurons. [13] Neurodegeneration begins in the brainstem and progresses to the olfactory bulb, substantia nigra, limbic areas, and the neocortex. [14] [13]", "contents": "Parkinson-Plus Syndrome -- Pathophysiology -- Lewy Body Dementia (LBD). In LBD, alpha-synuclein dysfunction and associated Lewy body deposits contribute to the impairment of particularly susceptible dopaminergic and cholinergic neurons. [13] Neurodegeneration begins in the brainstem and progresses to the olfactory bulb, substantia nigra, limbic areas, and the neocortex. [14] [13]"}
{"id": "article-143125_13", "title": "Parkinson-Plus Syndrome -- Pathophysiology -- Multiple System Atrophy (MSA)", "content": "MSA is suggested to be due to the prion-like spreading of alpha-synuclein proteins primarily, as well as glial cytoplasmic inclusions of tau and ubiquitin proteins. [15] Locations of pathology include the substantia nigra, Purkinje cells of the cerebellum, caudate nucleus, putamen, locus ceruleus, pontine nuclei, and inferior olivary nucleus. [16] [17]", "contents": "Parkinson-Plus Syndrome -- Pathophysiology -- Multiple System Atrophy (MSA). MSA is suggested to be due to the prion-like spreading of alpha-synuclein proteins primarily, as well as glial cytoplasmic inclusions of tau and ubiquitin proteins. [15] Locations of pathology include the substantia nigra, Purkinje cells of the cerebellum, caudate nucleus, putamen, locus ceruleus, pontine nuclei, and inferior olivary nucleus. [16] [17]"}
{"id": "article-143125_14", "title": "Parkinson-Plus Syndrome -- Pathophysiology -- Progressive Supranuclear Palsy (PSP)", "content": "PSP involves tau cytoplasmic inclusions within neurons, referred to as neurofibrillary tangles. [14] These inclusions lead to neuronal loss, gliosis, and damage to astrocytes and oligodendrocytes.\u00a0Areas targeted include the basal ganglia (substantia nigra, subthalamic nucleus, internal globus pallidus), oculomotor complex, cerebral cortex periaqueductal gray matter, superior colliculi, basis pontis, and dentate nucleus. [18]", "contents": "Parkinson-Plus Syndrome -- Pathophysiology -- Progressive Supranuclear Palsy (PSP). PSP involves tau cytoplasmic inclusions within neurons, referred to as neurofibrillary tangles. [14] These inclusions lead to neuronal loss, gliosis, and damage to astrocytes and oligodendrocytes.\u00a0Areas targeted include the basal ganglia (substantia nigra, subthalamic nucleus, internal globus pallidus), oculomotor complex, cerebral cortex periaqueductal gray matter, superior colliculi, basis pontis, and dentate nucleus. [18]"}
{"id": "article-143125_15", "title": "Parkinson-Plus Syndrome -- Pathophysiology -- Corticobasal Degeneration\u00a0(CBD)", "content": "CBD\u00a0is associated with\u00a0tau astrocytic plaques and inclusions in the glia.\u00a0These tau proteins lead to severe gliosis, neuronal loss, and ballooned achromatic neurons. [19] In CBD, there is prominent asymmetric frontoparietal atrophy. [19]", "contents": "Parkinson-Plus Syndrome -- Pathophysiology -- Corticobasal Degeneration\u00a0(CBD). CBD\u00a0is associated with\u00a0tau astrocytic plaques and inclusions in the glia.\u00a0These tau proteins lead to severe gliosis, neuronal loss, and ballooned achromatic neurons. [19] In CBD, there is prominent asymmetric frontoparietal atrophy. [19]"}
{"id": "article-143125_16", "title": "Parkinson-Plus Syndrome -- History and Physical", "content": "Parkinson-plus syndrome presents with parkinsonism as well as a variety of other clinical features that can be elicited by obtaining a focused history and physical\u00a0along with close neurological monitoring. As in classical PD, there is apraxia, rigidity, bradykinesia, tremor, and postural instability. [1]", "contents": "Parkinson-Plus Syndrome -- History and Physical. Parkinson-plus syndrome presents with parkinsonism as well as a variety of other clinical features that can be elicited by obtaining a focused history and physical\u00a0along with close neurological monitoring. As in classical PD, there is apraxia, rigidity, bradykinesia, tremor, and postural instability. [1]"}
{"id": "article-143125_17", "title": "Parkinson-Plus Syndrome -- History and Physical", "content": "Depending on the specific PPS, other possible clinical features include dementia, hallucinations, dysautonomia, symmetrical onset, myoclonus, pyramidal tract signs, supranuclear gaze palsy, and alien limb phenomenon. [5] PPS is also notable for its rapid progression and reduced response to classical PD medications.\u00a0As the disease progresses, patients experience difficulty with ambulation and activities of daily living, as well as an overall decline in function. [4] [5]", "contents": "Parkinson-Plus Syndrome -- History and Physical. Depending on the specific PPS, other possible clinical features include dementia, hallucinations, dysautonomia, symmetrical onset, myoclonus, pyramidal tract signs, supranuclear gaze palsy, and alien limb phenomenon. [5] PPS is also notable for its rapid progression and reduced response to classical PD medications.\u00a0As the disease progresses, patients experience difficulty with ambulation and activities of daily living, as well as an overall decline in function. [4] [5]"}
{"id": "article-143125_18", "title": "Parkinson-Plus Syndrome -- History and Physical -- Lewy Body Dementia", "content": "LBD consists of dementia characterized by deficits in attention, cognition, and visuospatial function.\u00a0Other notable features include visual hallucinations, rapid eye movement sleep behavior disorder (RBD), repeated falls, autonomic dysfunction, antipsychotic drug sensitivity, delusions, and depression.\u00a0LBD consists of two clinical entities: dementia with Lewy bodies and PD dementia. Dementia with Lewy bodies is classified as dementia occurring first or within one year of the movement disorder.\u00a0PD dementia occurs in a patient first receiving the diagnosis of PD and then developing dementia symptoms after one year or more of the diagnosis. [20]", "contents": "Parkinson-Plus Syndrome -- History and Physical -- Lewy Body Dementia. LBD consists of dementia characterized by deficits in attention, cognition, and visuospatial function.\u00a0Other notable features include visual hallucinations, rapid eye movement sleep behavior disorder (RBD), repeated falls, autonomic dysfunction, antipsychotic drug sensitivity, delusions, and depression.\u00a0LBD consists of two clinical entities: dementia with Lewy bodies and PD dementia. Dementia with Lewy bodies is classified as dementia occurring first or within one year of the movement disorder.\u00a0PD dementia occurs in a patient first receiving the diagnosis of PD and then developing dementia symptoms after one year or more of the diagnosis. [20]"}
{"id": "article-143125_19", "title": "Parkinson-Plus Syndrome -- History and Physical -- Multiple System Atrophy", "content": "The cardinal features of MSA are akinetic-rigid parkinsonism, cerebellar ataxia, autonomic failure, urogenital dysfunction, and pyramidal signs.\u00a0There are two clinical subtypes of MSA based on motor presentation: MSA with predominant parkinsonism (MSA-P) and MSA with predominant cerebellar ataxia (MSA-C). [5]", "contents": "Parkinson-Plus Syndrome -- History and Physical -- Multiple System Atrophy. The cardinal features of MSA are akinetic-rigid parkinsonism, cerebellar ataxia, autonomic failure, urogenital dysfunction, and pyramidal signs.\u00a0There are two clinical subtypes of MSA based on motor presentation: MSA with predominant parkinsonism (MSA-P) and MSA with predominant cerebellar ataxia (MSA-C). [5]"}
{"id": "article-143125_20", "title": "Parkinson-Plus Syndrome -- History and Physical -- Multiple System Atrophy", "content": "The predominant motor feature may also change as the disease progresses. MSA-P is associated with bradykinesia, postural instability, rigidity, and a jerky postural and action tremor.\u00a0MSA-C is characterized by gait and limb ataxia, dysarthria, and eye movement disturbances.\u00a0Dysautonomia in both motor subtypes is standard and includes early-onset erectile dysfunction, urinary frequency, incontinence, and late-appearing orthostatic hypotension. [21] Cognitive function in MSA is usually well preserved.", "contents": "Parkinson-Plus Syndrome -- History and Physical -- Multiple System Atrophy. The predominant motor feature may also change as the disease progresses. MSA-P is associated with bradykinesia, postural instability, rigidity, and a jerky postural and action tremor.\u00a0MSA-C is characterized by gait and limb ataxia, dysarthria, and eye movement disturbances.\u00a0Dysautonomia in both motor subtypes is standard and includes early-onset erectile dysfunction, urinary frequency, incontinence, and late-appearing orthostatic hypotension. [21] Cognitive function in MSA is usually well preserved."}
{"id": "article-143125_21", "title": "Parkinson-Plus Syndrome -- History and Physical -- Corticobasal Degeneration", "content": "CBD presents as an asymmetric movement disorder, with symptoms affecting one limb initially. Akinesia features\u00a0include extreme\u00a0rigidity, focal myoclonus, dystonia, alien limb phenomenon, and apraxia. [5] Cognitive impairment is common and may be the presenting feature. The cognitive decline includes aphasia, executive dysfunction, visuospatial deficits, and behavioral change.\u00a0Episodic memory is often preserved. [22]", "contents": "Parkinson-Plus Syndrome -- History and Physical -- Corticobasal Degeneration. CBD presents as an asymmetric movement disorder, with symptoms affecting one limb initially. Akinesia features\u00a0include extreme\u00a0rigidity, focal myoclonus, dystonia, alien limb phenomenon, and apraxia. [5] Cognitive impairment is common and may be the presenting feature. The cognitive decline includes aphasia, executive dysfunction, visuospatial deficits, and behavioral change.\u00a0Episodic memory is often preserved. [22]"}
{"id": "article-143125_22", "title": "Parkinson-Plus Syndrome -- History and Physical -- Progressive Supranuclear Palsy", "content": "PSP presents a variety of unique phenotypes. The most common and classic form of PSP is known as Richardson syndrome (PSP-RS).\u00a0PSP-RS initially presents with gait dysfunction that leads to frequent falls.\u00a0Supranuclear palsy is the hallmark of PSP, as patients cannot move the eyes vertically, focus on objects, or control eyelid movements.\u00a0Ophthalmoparesis usually appears within four years but may take up to 10 years to develop. [23]", "contents": "Parkinson-Plus Syndrome -- History and Physical -- Progressive Supranuclear Palsy. PSP presents a variety of unique phenotypes. The most common and classic form of PSP is known as Richardson syndrome (PSP-RS).\u00a0PSP-RS initially presents with gait dysfunction that leads to frequent falls.\u00a0Supranuclear palsy is the hallmark of PSP, as patients cannot move the eyes vertically, focus on objects, or control eyelid movements.\u00a0Ophthalmoparesis usually appears within four years but may take up to 10 years to develop. [23]"}
{"id": "article-143125_23", "title": "Parkinson-Plus Syndrome -- History and Physical -- Progressive Supranuclear Palsy", "content": "PSP patients are described as having axial rigidity and standing with an extended posture as opposed to the flexed posture in PD. Patients tend to pivot quickly and often fall backward.\u00a0Other common symptoms include dysphagia, dysarthria, rigidity, frontal cognitive dysfunction, and sleep abnormalities. [24]", "contents": "Parkinson-Plus Syndrome -- History and Physical -- Progressive Supranuclear Palsy. PSP patients are described as having axial rigidity and standing with an extended posture as opposed to the flexed posture in PD. Patients tend to pivot quickly and often fall backward.\u00a0Other common symptoms include dysphagia, dysarthria, rigidity, frontal cognitive dysfunction, and sleep abnormalities. [24]"}
{"id": "article-143125_24", "title": "Parkinson-Plus Syndrome -- History and Physical -- Progressive Supranuclear Palsy", "content": "Phenotypes of PSP include PSP with predominant oculomotor dysfunction (PSP-OM), postural instability (PSP-PI), frontal presentation (PSP-F), speech/language disorder (PSP-SL), corticobasal syndrome (PSP-CBS), and progressive gait freezing (PSP-PGF).", "contents": "Parkinson-Plus Syndrome -- History and Physical -- Progressive Supranuclear Palsy. Phenotypes of PSP include PSP with predominant oculomotor dysfunction (PSP-OM), postural instability (PSP-PI), frontal presentation (PSP-F), speech/language disorder (PSP-SL), corticobasal syndrome (PSP-CBS), and progressive gait freezing (PSP-PGF)."}
{"id": "article-143125_25", "title": "Parkinson-Plus Syndrome -- Evaluation", "content": "Although Parkinson-plus syndrome is a clinical diagnosis, a full medical workup consists of detailed laboratory testing and imaging studies to help rule out other common diagnoses. Unfortunately, in most PPS conditions, laboratory and imaging findings are non-diagnostic. [1] [2] [4]", "contents": "Parkinson-Plus Syndrome -- Evaluation. Although Parkinson-plus syndrome is a clinical diagnosis, a full medical workup consists of detailed laboratory testing and imaging studies to help rule out other common diagnoses. Unfortunately, in most PPS conditions, laboratory and imaging findings are non-diagnostic. [1] [2] [4]"}
{"id": "article-143125_26", "title": "Parkinson-Plus Syndrome -- Evaluation -- Lewy Dody Dementia", "content": "The evaluation of LBD begins as an analysis of dementia. This consists of a cognitive assessment with a Mini-Mental State Examination (MMSE) or Montreal Cognitive Assessment (MoCA).\u00a0Laboratory testing includes a basic workup with a chemistry panel, complete blood count (CBC), thyroid function test, and vitamin B12 levels. Neuroimaging is performed with computed tomography (CT) or magnetic resonance imaging (MRI). Imaging findings in LBD include generalized brain atrophy and white matter lesions, pronounced cortical atrophy, degeneration of the putamen, and reduced perfusion, most marked in the occipital areas. [20]", "contents": "Parkinson-Plus Syndrome -- Evaluation -- Lewy Dody Dementia. The evaluation of LBD begins as an analysis of dementia. This consists of a cognitive assessment with a Mini-Mental State Examination (MMSE) or Montreal Cognitive Assessment (MoCA).\u00a0Laboratory testing includes a basic workup with a chemistry panel, complete blood count (CBC), thyroid function test, and vitamin B12 levels. Neuroimaging is performed with computed tomography (CT) or magnetic resonance imaging (MRI). Imaging findings in LBD include generalized brain atrophy and white matter lesions, pronounced cortical atrophy, degeneration of the putamen, and reduced perfusion, most marked in the occipital areas. [20]"}
{"id": "article-143125_27", "title": "Parkinson-Plus Syndrome -- Evaluation -- Lewy Dody Dementia", "content": "Indicative biomarkers that contribute to the diagnosis of LBD include reduced dopamine transporter uptake in the basal ganglia evident on positron emission tomography (PET) or single-photon emission computerized tomography (SPECT), low uptake of 123-iodine-metaiodobenzylguanidine (MIBG) myocardial scintigraphy, and confirmation of REM sleep without atonia on polysomnography.\u00a0Supportive biomarkers for diagnosis include relative preservation of medial temporal lobe structures on CT or MRI, low uptake on PET perfusion scans with reduced occipital activity, and posterior slow-wave activity on electroencephalogram (EEG) with periodic fluctuations in the pre-alpha and theta range. [20]", "contents": "Parkinson-Plus Syndrome -- Evaluation -- Lewy Dody Dementia. Indicative biomarkers that contribute to the diagnosis of LBD include reduced dopamine transporter uptake in the basal ganglia evident on positron emission tomography (PET) or single-photon emission computerized tomography (SPECT), low uptake of 123-iodine-metaiodobenzylguanidine (MIBG) myocardial scintigraphy, and confirmation of REM sleep without atonia on polysomnography.\u00a0Supportive biomarkers for diagnosis include relative preservation of medial temporal lobe structures on CT or MRI, low uptake on PET perfusion scans with reduced occipital activity, and posterior slow-wave activity on electroencephalogram (EEG) with periodic fluctuations in the pre-alpha and theta range. [20]"}
{"id": "article-143125_28", "title": "Parkinson-Plus Syndrome -- Evaluation -- Multiple System Atrophy", "content": "As in other PPS diseases, laboratory and imaging studies are\u00a0non-specific, and diagnosis is based on clinical features. Neuroimaging is used to rule out other diseases but may also show atrophy of the putamen, pons, or middle cerebellar peduncle, along with signal changes in the putamen.\u00a0A definite diagnosis of MSA is based on post-mortem neurodegenerative changes in the striatonigral or olivopontocerebellar structures, with pathology showing alpha-synuclein inclusions in glial cells. [25] Other useful tests include autonomic function testing and bladder function analysis with sphincter electromyography (EMG). [26] [27]", "contents": "Parkinson-Plus Syndrome -- Evaluation -- Multiple System Atrophy. As in other PPS diseases, laboratory and imaging studies are\u00a0non-specific, and diagnosis is based on clinical features. Neuroimaging is used to rule out other diseases but may also show atrophy of the putamen, pons, or middle cerebellar peduncle, along with signal changes in the putamen.\u00a0A definite diagnosis of MSA is based on post-mortem neurodegenerative changes in the striatonigral or olivopontocerebellar structures, with pathology showing alpha-synuclein inclusions in glial cells. [25] Other useful tests include autonomic function testing and bladder function analysis with sphincter electromyography (EMG). [26] [27]"}
{"id": "article-143125_29", "title": "Parkinson-Plus Syndrome -- Evaluation -- Corticobasal Degeneration", "content": "No established biological markers exist for CBD. Routine blood, urine, and cerebrospinal fluid (CSF) analyses are all non-diagnostic, while neuroimaging studies are non-specific. Workup includes laboratory tests such as CBC, electrolytes, vitamin B12, thyroid function tests, syphilis testing (to investigate for causes of cognitive deficits), and copper and ceruloplasmin levels to rule out Wilson's disease. Workup includes erythrocyte sedimentation rate (ESR), antinuclear antibody (ANA), and liver function tests\u00a0to investigate rheumatologic disease; CSF testing for biomarkers of neurodegeneration can be performed, such as analysis for 14-3-3 protein, neuron-specific enolase, and CSF real-time quaking-induced conversion (CSF RT-QuIC) to test for prionopathies such as Creutzfeldt-Jakob disease (CJD).", "contents": "Parkinson-Plus Syndrome -- Evaluation -- Corticobasal Degeneration. No established biological markers exist for CBD. Routine blood, urine, and cerebrospinal fluid (CSF) analyses are all non-diagnostic, while neuroimaging studies are non-specific. Workup includes laboratory tests such as CBC, electrolytes, vitamin B12, thyroid function tests, syphilis testing (to investigate for causes of cognitive deficits), and copper and ceruloplasmin levels to rule out Wilson's disease. Workup includes erythrocyte sedimentation rate (ESR), antinuclear antibody (ANA), and liver function tests\u00a0to investigate rheumatologic disease; CSF testing for biomarkers of neurodegeneration can be performed, such as analysis for 14-3-3 protein, neuron-specific enolase, and CSF real-time quaking-induced conversion (CSF RT-QuIC) to test for prionopathies such as Creutzfeldt-Jakob disease (CJD)."}
{"id": "article-143125_30", "title": "Parkinson-Plus Syndrome -- Evaluation -- Corticobasal Degeneration", "content": "Evaluation for AD can be performed by testing for Amyloid beta-42, phosphorylated tau, and total tau.\u00a0Regarding neuroimaging, CBD has been shown to have more asymmetric atrophy of the frontal and parietal lobes. [28] Cortical atrophy is observed mainly in the central sulci, supplementary motor area, and superior frontal gyrus.\u00a0PET and SPECT imaging demonstrate asymmetric activity in the subcortical basal ganglia and cortical frontal-parietal regions. [28]", "contents": "Parkinson-Plus Syndrome -- Evaluation -- Corticobasal Degeneration. Evaluation for AD can be performed by testing for Amyloid beta-42, phosphorylated tau, and total tau.\u00a0Regarding neuroimaging, CBD has been shown to have more asymmetric atrophy of the frontal and parietal lobes. [28] Cortical atrophy is observed mainly in the central sulci, supplementary motor area, and superior frontal gyrus.\u00a0PET and SPECT imaging demonstrate asymmetric activity in the subcortical basal ganglia and cortical frontal-parietal regions. [28]"}
{"id": "article-143125_31", "title": "Parkinson-Plus Syndrome -- Evaluation -- Progressive Supranuclear Palsy", "content": "In PSP, a medical workup is based upon eliminating other diagnoses. Although not diagnostic, neuroimaging is notable for the hummingbird sign (or penguin silhouette sign) on MRI, a name derived from predominant midbrain atrophy with preserved pons resembling a hummingbird or penguin in silhouette.\u00a0PET studies have shown hypometabolism in the frontal cortex, putamen, caudate, thalamus, and brainstem. Fluorodopa (F-dopa) PET study demonstrates a lower influx of F-dopa in the caudate and putamen compared to PD.", "contents": "Parkinson-Plus Syndrome -- Evaluation -- Progressive Supranuclear Palsy. In PSP, a medical workup is based upon eliminating other diagnoses. Although not diagnostic, neuroimaging is notable for the hummingbird sign (or penguin silhouette sign) on MRI, a name derived from predominant midbrain atrophy with preserved pons resembling a hummingbird or penguin in silhouette.\u00a0PET studies have shown hypometabolism in the frontal cortex, putamen, caudate, thalamus, and brainstem. Fluorodopa (F-dopa) PET study demonstrates a lower influx of F-dopa in the caudate and putamen compared to PD."}
{"id": "article-143125_32", "title": "Parkinson-Plus Syndrome -- Evaluation -- Progressive Supranuclear Palsy", "content": "Furthermore, sleep studies are often abnormal in PSP patients with lower total sleep time, loss of REM sleep, and increased awakenings.\u00a0Histologic findings in PSP show prominent involvement in the basal ganglia (specifically the internal globus pallidus, subthalamic nucleus, and substantia nigra), oculomotor complex, superior colliculi, dentate nucleus, periaqueductal gray matter, and basis pontis.", "contents": "Parkinson-Plus Syndrome -- Evaluation -- Progressive Supranuclear Palsy. Furthermore, sleep studies are often abnormal in PSP patients with lower total sleep time, loss of REM sleep, and increased awakenings.\u00a0Histologic findings in PSP show prominent involvement in the basal ganglia (specifically the internal globus pallidus, subthalamic nucleus, and substantia nigra), oculomotor complex, superior colliculi, dentate nucleus, periaqueductal gray matter, and basis pontis."}
{"id": "article-143125_33", "title": "Parkinson-Plus Syndrome -- Treatment / Management", "content": "In general, there are no disease-modifying treatments for PPS conditions. Treatment is focused on symptom management and improving quality of life. A minority of patients may show some relief of parkinsonism symptoms with levodopa.\u00a0Alternative agents with limited benefit for parkinsonism include monoamine oxidase type B (MAO-B) inhibitor selegiline, the dopamine-releasing agent amantadine, and dopamine receptor agonists.", "contents": "Parkinson-Plus Syndrome -- Treatment / Management. In general, there are no disease-modifying treatments for PPS conditions. Treatment is focused on symptom management and improving quality of life. A minority of patients may show some relief of parkinsonism symptoms with levodopa.\u00a0Alternative agents with limited benefit for parkinsonism include monoamine oxidase type B (MAO-B) inhibitor selegiline, the dopamine-releasing agent amantadine, and dopamine receptor agonists."}
{"id": "article-143125_34", "title": "Parkinson-Plus Syndrome -- Treatment / Management", "content": "Managing tremors includes using propranolol, clonazepam, topiramate, and gabapentin.\u00a0Anticholinergics and baclofen may be helpful.\u00a0Physical therapy helps prevent falls, reduces contractures, and promotes mobility.\u00a0Physical therapists  can also help with movement problems through cardiovascular, strengthening, flexibility exercises, gait training, and general fitness programs.", "contents": "Parkinson-Plus Syndrome -- Treatment / Management. Managing tremors includes using propranolol, clonazepam, topiramate, and gabapentin.\u00a0Anticholinergics and baclofen may be helpful.\u00a0Physical therapy helps prevent falls, reduces contractures, and promotes mobility.\u00a0Physical therapists  can also help with movement problems through cardiovascular, strengthening, flexibility exercises, gait training, and general fitness programs."}
{"id": "article-143125_35", "title": "Parkinson-Plus Syndrome -- Treatment / Management", "content": "Occupational therapy can assist in promoting independence for activities of daily living.\u00a0Speech therapy is important in evaluating dysphagia, while dieticians can assist in proper nutrition planning.\u00a0Palliative and safety measures are important for end-of-life care and limiting stress for the patient and caregivers. [5]", "contents": "Parkinson-Plus Syndrome -- Treatment / Management. Occupational therapy can assist in promoting independence for activities of daily living.\u00a0Speech therapy is important in evaluating dysphagia, while dieticians can assist in proper nutrition planning.\u00a0Palliative and safety measures are important for end-of-life care and limiting stress for the patient and caregivers. [5]"}
{"id": "article-143125_36", "title": "Parkinson-Plus Syndrome -- Treatment / Management", "content": "Music or expressive arts therapists\u00a0may provide meaningful activities that can reduce anxiety and improve well-being. There are also various other treatments and therapies which are specific for individual PPS diseases.", "contents": "Parkinson-Plus Syndrome -- Treatment / Management. Music or expressive arts therapists\u00a0may provide meaningful activities that can reduce anxiety and improve well-being. There are also various other treatments and therapies which are specific for individual PPS diseases."}
{"id": "article-143125_37", "title": "Parkinson-Plus Syndrome -- Treatment / Management -- Lewy Body Dementia", "content": "In LBD, cholinesterase inhibitors or memantine can be used to treat cognitive or behavioral symptoms.\u00a0Antipsychotic medications are used when behavioral symptoms are severe.\u00a0Disabling parkinsonism can be treated with levodopa, although effects are limited. [20] REM sleep behavior disorder is treated with melatonin or clonazepam.\u00a0Mental health counselors\u00a0can help LBD patients manage difficult emotions and behaviors.", "contents": "Parkinson-Plus Syndrome -- Treatment / Management -- Lewy Body Dementia. In LBD, cholinesterase inhibitors or memantine can be used to treat cognitive or behavioral symptoms.\u00a0Antipsychotic medications are used when behavioral symptoms are severe.\u00a0Disabling parkinsonism can be treated with levodopa, although effects are limited. [20] REM sleep behavior disorder is treated with melatonin or clonazepam.\u00a0Mental health counselors\u00a0can help LBD patients manage difficult emotions and behaviors."}
{"id": "article-143125_38", "title": "Parkinson-Plus Syndrome -- Treatment / Management -- Multiple System Atrophy", "content": "Botulinum toxin injections may alleviate focal dystonias in MSA.\u00a0Chronic orthostatic hypotension resulting from autonomic dysfunction can be improved with fludrocortisone acetate or midodrine.\u00a0REM sleep behavior disorder can be treated with melatonin or clonazepam if necessary. [29]", "contents": "Parkinson-Plus Syndrome -- Treatment / Management -- Multiple System Atrophy. Botulinum toxin injections may alleviate focal dystonias in MSA.\u00a0Chronic orthostatic hypotension resulting from autonomic dysfunction can be improved with fludrocortisone acetate or midodrine.\u00a0REM sleep behavior disorder can be treated with melatonin or clonazepam if necessary. [29]"}
{"id": "article-143125_39", "title": "Parkinson-Plus Syndrome -- Treatment / Management -- Corticobasal Degeneration", "content": "In CBD, dystonia can be treated with botulinum toxin to improve function in the affected limb. [29] Clonazepam is the agent of choice for treating myoclonus.\u00a0Acetylcholinesterase inhibitors such as donepezil or rivastigmine can be attempted to treat cognitive deficits. [30]", "contents": "Parkinson-Plus Syndrome -- Treatment / Management -- Corticobasal Degeneration. In CBD, dystonia can be treated with botulinum toxin to improve function in the affected limb. [29] Clonazepam is the agent of choice for treating myoclonus.\u00a0Acetylcholinesterase inhibitors such as donepezil or rivastigmine can be attempted to treat cognitive deficits. [30]"}
{"id": "article-143125_40", "title": "Parkinson-Plus Syndrome -- Treatment / Management -- Progressive Supranuclear Palsy", "content": "There are a variety of therapeutic options to address the ophthalmological symptoms of PSP. Patients with limited extraocular movements can use mirror-prism lenses to read and perform activities of daily living with more independence.\u00a0Eyelid opening apraxia and blepharospasm can be relieved with eyelid crutches and botulinum toxin. [29] Artificial tears should be used for treating a decreased blink rate, and dark glasses can reduce photophobia.", "contents": "Parkinson-Plus Syndrome -- Treatment / Management -- Progressive Supranuclear Palsy. There are a variety of therapeutic options to address the ophthalmological symptoms of PSP. Patients with limited extraocular movements can use mirror-prism lenses to read and perform activities of daily living with more independence.\u00a0Eyelid opening apraxia and blepharospasm can be relieved with eyelid crutches and botulinum toxin. [29] Artificial tears should be used for treating a decreased blink rate, and dark glasses can reduce photophobia."}
{"id": "article-143125_41", "title": "Parkinson-Plus Syndrome -- Differential Diagnosis", "content": "Each Parkinson-plus syndrome disease and classical PD must be considered when forming a differential diagnosis. Other similar diagnoses include AD, vascular dementia, normal pressure hydrocephalus, CJD, and certain psychiatric diseases. [1] [2] Extrapyramidal side effects of medications can also be a cause of parkinsonism. [4]", "contents": "Parkinson-Plus Syndrome -- Differential Diagnosis. Each Parkinson-plus syndrome disease and classical PD must be considered when forming a differential diagnosis. Other similar diagnoses include AD, vascular dementia, normal pressure hydrocephalus, CJD, and certain psychiatric diseases. [1] [2] Extrapyramidal side effects of medications can also be a cause of parkinsonism. [4]"}
{"id": "article-143125_42", "title": "Parkinson-Plus Syndrome -- Prognosis", "content": "Compared to idiopathic PD, PPS conditions progress more rapidly and culminate in death earlier. [1] [2] [4]", "contents": "Parkinson-Plus Syndrome -- Prognosis. Compared to idiopathic PD, PPS conditions progress more rapidly and culminate in death earlier. [1] [2] [4]"}
{"id": "article-143125_43", "title": "Parkinson-Plus Syndrome -- Prognosis -- Lewy Body Disease", "content": "In LBD, symptoms progress rapidly, with an estimated survival of 1.8 to 9.5 years.\u00a0Studies show that survival for LBD is shorter compared to AD.\u00a0Cognitive decline is progressive, and the median time to severe dementia is\u00a0approximately five years.\u00a0Parkinsonism and non-motor symptoms, including autonomic dysfunction and neuropsychiatric deficits, worsen over time. [20] Behavioral symptoms such as hallucinations, delusions, depression, and anxiety\u00a0may require nursing home admission.", "contents": "Parkinson-Plus Syndrome -- Prognosis -- Lewy Body Disease. In LBD, symptoms progress rapidly, with an estimated survival of 1.8 to 9.5 years.\u00a0Studies show that survival for LBD is shorter compared to AD.\u00a0Cognitive decline is progressive, and the median time to severe dementia is\u00a0approximately five years.\u00a0Parkinsonism and non-motor symptoms, including autonomic dysfunction and neuropsychiatric deficits, worsen over time. [20] Behavioral symptoms such as hallucinations, delusions, depression, and anxiety\u00a0may require nursing home admission."}
{"id": "article-143125_44", "title": "Parkinson-Plus Syndrome -- Prognosis -- Multiple System Atrophy", "content": "Compared to idiopathic PD, the disease progression of MSA is much quicker.\u00a0From symptom onset, autonomic dysfunction begins\u00a0in 2.5 years, wheelchair confinement occurs in 3.5 to 5 years, and patients are bedridden for 5 to 8 years.\u00a0Following diagnosis, death occurs after 6 to 10 years in most patients. [29]", "contents": "Parkinson-Plus Syndrome -- Prognosis -- Multiple System Atrophy. Compared to idiopathic PD, the disease progression of MSA is much quicker.\u00a0From symptom onset, autonomic dysfunction begins\u00a0in 2.5 years, wheelchair confinement occurs in 3.5 to 5 years, and patients are bedridden for 5 to 8 years.\u00a0Following diagnosis, death occurs after 6 to 10 years in most patients. [29]"}
{"id": "article-143125_45", "title": "Parkinson-Plus Syndrome -- Prognosis -- Corticobasal Degeneration", "content": "CBD progresses rapidly to death, with the most common cause of mortality being complications from immobility or dysphagia (pneumonia and sepsis). [31] From the onset of symptoms, the median survival time is approximately 6 to 8 years but ranges from 2 to 13 years. [32]", "contents": "Parkinson-Plus Syndrome -- Prognosis -- Corticobasal Degeneration. CBD progresses rapidly to death, with the most common cause of mortality being complications from immobility or dysphagia (pneumonia and sepsis). [31] From the onset of symptoms, the median survival time is approximately 6 to 8 years but ranges from 2 to 13 years. [32]"}
{"id": "article-143125_46", "title": "Parkinson-Plus Syndrome -- Prognosis -- Progressive Supranuclear Palsy", "content": "The progression of PSP is rapid, and patients usually become dependent on care within three to four years from symptom onset.\u00a0Death occurs approximately six to nine years after the diagnosis. [18] Shorter survival is seen more in the PSP-RS phenotype compared to the other variants. [29]", "contents": "Parkinson-Plus Syndrome -- Prognosis -- Progressive Supranuclear Palsy. The progression of PSP is rapid, and patients usually become dependent on care within three to four years from symptom onset.\u00a0Death occurs approximately six to nine years after the diagnosis. [18] Shorter survival is seen more in the PSP-RS phenotype compared to the other variants. [29]"}
{"id": "article-143125_47", "title": "Parkinson-Plus Syndrome -- Complications", "content": "There are various complications in PPS. These are often related to aspects of dementia and parkinsonism. Complications of parkinsonism include immobility and falls.\u00a0Dysphagia can result in aspiration pneumonia and sepsis in many of these diseases.\u00a0Urinary tract abnormalities may lead to complications like urinary tract infections. [6]", "contents": "Parkinson-Plus Syndrome -- Complications. There are various complications in PPS. These are often related to aspects of dementia and parkinsonism. Complications of parkinsonism include immobility and falls.\u00a0Dysphagia can result in aspiration pneumonia and sepsis in many of these diseases.\u00a0Urinary tract abnormalities may lead to complications like urinary tract infections. [6]"}
{"id": "article-143125_48", "title": "Parkinson-Plus Syndrome -- Complications", "content": "Frequently, medications present many unwanted side effects. Furthermore, autonomic dysfunction can present with cardiac complications. [7] Often overlooked, behavioral symptoms such as anxiety and depression lead to suicidal ideation. [8]", "contents": "Parkinson-Plus Syndrome -- Complications. Frequently, medications present many unwanted side effects. Furthermore, autonomic dysfunction can present with cardiac complications. [7] Often overlooked, behavioral symptoms such as anxiety and depression lead to suicidal ideation. [8]"}
{"id": "article-143125_49", "title": "Parkinson-Plus Syndrome -- Deterrence and Patient Education", "content": "Patient and caregiver education in the context of Parkinson-plus syndrome is crucial and can result in improved disease management, better functional outcomes, and higher quality of life. [2] Patients and families should be aware that PPS conditions progress rapidly, but there are many treatments and therapies that can provide benefits. [2]", "contents": "Parkinson-Plus Syndrome -- Deterrence and Patient Education. Patient and caregiver education in the context of Parkinson-plus syndrome is crucial and can result in improved disease management, better functional outcomes, and higher quality of life. [2] Patients and families should be aware that PPS conditions progress rapidly, but there are many treatments and therapies that can provide benefits. [2]"}
{"id": "article-143125_50", "title": "Parkinson-Plus Syndrome -- Deterrence and Patient Education", "content": "The various healthcare professionals should provide education to help manage the disease. Patients and families must acknowledge the symptoms of PPS, including cognitive decline, motor deficits, behavioral changes, hallucinations, and autonomic dysfunction. [1] There are many complications of these conditions. Therefore, a focus on preventing and deterring further comorbidities is crucial. [4]", "contents": "Parkinson-Plus Syndrome -- Deterrence and Patient Education. The various healthcare professionals should provide education to help manage the disease. Patients and families must acknowledge the symptoms of PPS, including cognitive decline, motor deficits, behavioral changes, hallucinations, and autonomic dysfunction. [1] There are many complications of these conditions. Therefore, a focus on preventing and deterring further comorbidities is crucial. [4]"}
{"id": "article-143125_51", "title": "Parkinson-Plus Syndrome -- Enhancing Healthcare Team Outcomes", "content": "In managing PPS, an interdisciplinary approach is essential. It should involve healthcare professionals from primary care, neurology, radiology, psychiatry, occupational therapy, physical therapy, speech pathology, nutrition, neuropsychology, social work, palliative care, and specialty-trained nursing. [1] [2]", "contents": "Parkinson-Plus Syndrome -- Enhancing Healthcare Team Outcomes. In managing PPS, an interdisciplinary approach is essential. It should involve healthcare professionals from primary care, neurology, radiology, psychiatry, occupational therapy, physical therapy, speech pathology, nutrition, neuropsychology, social work, palliative care, and specialty-trained nursing. [1] [2]"}
{"id": "article-143125_52", "title": "Parkinson-Plus Syndrome -- Enhancing Healthcare Team Outcomes", "content": "Collaboration among interprofessional healthcare\u00a0team members can enhance disease management and improve functional outcomes for patients.\u00a0Because\u00a0PPS conditions\u00a0advance rapidly and result in profound functional impairments, healthcare professionals must coordinate care promptly to limit disease progression and alleviate debilitating symptoms.\u00a0Medications require strict management to maximize therapeutic benefits and limit harmful side effects. Therapies and support services provided early in the disease course can improve patient function and limit the development of comorbidities. [2] This includes contributions from clinicians, nurses, pharmacists, and therapists, all engaged in open communication and contributing from their areas of expertise to achieve the best possible patient outcomes. [Level 5]", "contents": "Parkinson-Plus Syndrome -- Enhancing Healthcare Team Outcomes. Collaboration among interprofessional healthcare\u00a0team members can enhance disease management and improve functional outcomes for patients.\u00a0Because\u00a0PPS conditions\u00a0advance rapidly and result in profound functional impairments, healthcare professionals must coordinate care promptly to limit disease progression and alleviate debilitating symptoms.\u00a0Medications require strict management to maximize therapeutic benefits and limit harmful side effects. Therapies and support services provided early in the disease course can improve patient function and limit the development of comorbidities. [2] This includes contributions from clinicians, nurses, pharmacists, and therapists, all engaged in open communication and contributing from their areas of expertise to achieve the best possible patient outcomes. [Level 5]"}
{"id": "article-143125_53", "title": "Parkinson-Plus Syndrome -- Enhancing Healthcare Team Outcomes", "content": "Since the prognosis is poor and most patients end up in long-term facilities where the quality of life might not be optimal, caregiver education is vital to improve care for patients while they are at home. [29] Home care nurses can play a significant role in regularly monitoring patients for disease progression or developing new health issues that require further specialist attention. [6]", "contents": "Parkinson-Plus Syndrome -- Enhancing Healthcare Team Outcomes. Since the prognosis is poor and most patients end up in long-term facilities where the quality of life might not be optimal, caregiver education is vital to improve care for patients while they are at home. [29] Home care nurses can play a significant role in regularly monitoring patients for disease progression or developing new health issues that require further specialist attention. [6]"}
{"id": "article-143125_54", "title": "Parkinson-Plus Syndrome -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Parkinson-Plus Syndrome -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}